Table 1.

Long-term outcome parameters (N = 228)

Sex
Female	96 (42.1%)
Age
Mean 72.4 ± 12.2 [min 29; max 97], median 73 years
Interview partner
Patient	146 (64.0%)
Family member	81 (35.5%)
Caregiver	1 (0.4%)
Interval between stroke and telephone interview
949.6 ± 358.9 days [min 303; max 2082 days]; median 906 days (= 2.5 years)
Long-term outcome of stroke (N = 206)
mRS at telephone interview	2.0 ± 1.9 (median 1)
Mobility EQ-5D-5L	2.0 ± 1.4 (median 1)
Self-care EQ-5D-5L	1.7 ± 1.3 (median 1)
Usual activities EQ-5D-5L	1.9 ± 1.4 (median 1)
Pain/Discomfort EQ-5D-5L	1.7 ± 1.1 (median 1)
Anxiety/Depression EQ-5D-5L	1.7 ± 1.0 (median 1)
EQ-5D VAS	64.5 ± 21.0 (median 70)
EQ-5D-Index	0.777 ± 0.287 (median 0.915)
German level of care before stroke event (N = 205)
Level 0	180 (87.8%)
Level 1	3 (1.5%)
Level 2	13 (6.3%)
Level 3	6 (2.9%)
Level 4	3 (1.5%)
Level 5	0 (0%)
German level of care at telephone interview (N = 176)
Level 0	109 (61.9%)
Level 1	12 (6.8%)
Level 2	19 (10.8%)
Level 3	19 (10.8%)
Level 4	13 (7.4%)
Level 5	4 (2.3%)
Living situation (N = 206)
Independent	145 (70.4%)
Support from relatives or partner	29 (14.1%)
Care assistance at home	16 (7.8%)
Sheltered housing	5 (2.4%)
Care home	11 (5.3%)
Professional activity (N = 206)
Unchanged after stroke	26 (12.6%)
Reduced due to stroke event	12 (5.8%)
No longer employed due to stroke event	8 (3.9%)
Retired (regardless of stroke event or retired before stroke event)	160 (77.7%)
Recurrence of stroke (N = 214)
Recurrence	28 (13.1%)
No recurrence	186 (86.9%)
Unknown	14
Therapy
Antiplatelet drugs	133/196 (67.9%)
Statin therapy	150/196 (76.5%)
Oral anticoagulation	57/196 (29.1%)
Phenprocoumon	4/57
Apixaban	35/57
Dabigatran	9/57
Edoxaban	3/57
Rivaroxaban	5/57
Unknown	1/57
Antihypertensive therapy	163/196 (83.2%)
Antidepressive therapy	31/196 (15.8%)
Anticonvulsive therapy	9/196 (4.6%)
After discharge hospitalization for other reasons (N = 199)
Yes	61/199 (30.7%)
Died after discharge
Yes	22/228 (9.6%)